Alert detail
FDA Approval: OZEMPIC (SEMAGLUTIDE) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA209637Specialty: Multi-specialtyAdded: 6/6/2026Effective: 2017-12-05billing update
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.